Search Results
You are looking at 1 - 6 of 6 items for
- Author: Matti Poutanen x
- Refine by access: Content accessible to me x
Search for other papers by Matti Poutanen in
Google Scholar
PubMed
Search for other papers by Taija Saloniemi in
Google Scholar
PubMed
Search for other papers by Heli Jokela in
Google Scholar
PubMed
Department of Physiology, Turku Center for Disease Modeling, Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, FI-20014 Turku, Finland
Search for other papers by Leena Strauss in
Google Scholar
PubMed
Department of Physiology, Turku Center for Disease Modeling, Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, FI-20014 Turku, Finland
Search for other papers by Pirjo Pakarinen in
Google Scholar
PubMed
Department of Physiology, Turku Center for Disease Modeling, Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, FI-20014 Turku, Finland
Search for other papers by Matti Poutanen in
Google Scholar
PubMed
Disturbed action of sex steroid hormones, i.e. androgens and estrogens, is involved in the pathogenesis of various severe diseases in humans. Interestingly, recent studies have provided data further supporting the hypothesis that the circulating hormone concentrations do not explain all physiological and pathological processes observed in hormone-dependent tissues, while the intratissue sex steroid concentrations are determined by the expression of steroid metabolising enzymes in the neighbouring cells (paracrine action) and/or by target cells themselves (intracrine action). This local sex steroid production is also a valuable treatment option for developing novel therapies against hormonal diseases. Hydroxysteroid (17β) dehydrogenases (HSD17Bs) compose a family of 14 enzymes that catalyse the conversion between the low-active 17-keto steroids and the highly active 17β-hydroxy steroids. The enzymes frequently expressed in sex steroid target tissues are, thus, potential drug targets in order to lower the local sex steroid concentrations. The present review summarises the recent data obtained for the role of HSD17B1, HSD17B2, HSD17B7 and HSD17B12 enzymes in various metabolic pathways and their physiological and pathophysiological roles as revealed by the recently generated genetically modified mouse models. Our data, together with that provided by others, show that, in addition to having a role in sex steroid metabolism, several of these HSD17B enzymes possess key roles in other metabolic processes: for example, HD17B7 is essential for cholesterol biosynthesis and HSD17B12 is involved in elongation of fatty acids. Additional studies in vitro and in vivo are to be carried out in order to fully define the metabolic role of the HSD17B enzymes and to evaluate their value as drug targets.
Search for other papers by Laura D Ratner in
Google Scholar
PubMed
Hospital General de Agudos J. M. Ramos Mejía, Buenos Aires, Argentina
Search for other papers by Guillermina Stevens in
Google Scholar
PubMed
Search for other papers by Maria Marta Bonaventura in
Google Scholar
PubMed
Search for other papers by Victoria A Lux-Lantos in
Google Scholar
PubMed
Turku Center for Disease Modeling, University of Turku, Turku, Finland
Search for other papers by Matti Poutanen in
Google Scholar
PubMed
Search for other papers by Ricardo S Calandra in
Google Scholar
PubMed
Department of Surgery and Cancer, Imperial College London, London, UK
Search for other papers by Ilpo T Huhtaniemi in
Google Scholar
PubMed
Search for other papers by Susana B Rulli in
Google Scholar
PubMed
The metabolic syndrome is a growing epidemic; it increases the risk for diabetes, cardiovascular disease, fatty liver, and several cancers. Several reports have indicated a link between hormonal imbalances and insulin resistance or obesity. Transgenic (TG) female mice overexpressing the human chorionic gonadotropin β-subunit (hCGβ+ mice) exhibit constitutively elevated levels of hCG, increased production of testosterone, progesterone and prolactin, and obesity. The objective of this study was to investigate the influence of hCG hypersecretion on possible alterations in the glucose and lipid metabolism of adult TG females. We evaluated fasting serum insulin, glucose, and triglyceride levels in adult hCGβ+ females and conducted intraperitoneal glucose and insulin tolerance tests at different ages. TG female mice showed hyperinsulinemia, hypertriglyceridemia, and dyslipidemia, as well as glucose intolerance and insulin resistance at 6 months of age. A 1-week treatment with the dopamine agonist cabergoline applied on 5-week-old hCGβ+ mice, which corrected hyperprolactinemia, hyperandrogenism, and hyperprogesteronemia, effectively prevented the metabolic alterations. These data indicate a key role of the hyperprolactinemia-induced gonadal dysfunction in the metabolic disturbances of hCGβ+ female mice. The findings prompt further studies on the involvement of gonadotropins and prolactin on metabolic disorders and might pave the way for the development of new therapeutic strategies.
Search for other papers by Claes Ohlsson in
Google Scholar
PubMed
Search for other papers by Petra Henning in
Google Scholar
PubMed
Search for other papers by Karin H Nilsson in
Google Scholar
PubMed
Search for other papers by Jianyao Wu in
Google Scholar
PubMed
Search for other papers by Karin L Gustafsson in
Google Scholar
PubMed
Search for other papers by Klara Sjögren in
Google Scholar
PubMed
Search for other papers by Anna Törnqvist in
Google Scholar
PubMed
Search for other papers by Antti Koskela in
Google Scholar
PubMed
Search for other papers by Fu-Ping Zhang in
Google Scholar
PubMed
Search for other papers by Marie K Lagerquist in
Google Scholar
PubMed
Research Centre for Integrative Physiology and Pharmacology, Turku Center for Disease Modeling, Institute of Biomedicine, University of Turku, Turku, Finland
Search for other papers by Matti Poutanen in
Google Scholar
PubMed
Search for other papers by Juha Tuukkanen in
Google Scholar
PubMed
Search for other papers by Ulf H Lerner in
Google Scholar
PubMed
Search for other papers by Sofia Movérare-Skrtic in
Google Scholar
PubMed
Substantial progress has been made in the therapeutic reduction of vertebral fracture risk in patients with osteoporosis, but non-vertebral fracture risk has been improved only marginally. Human genetic studies demonstrate that the WNT16 locus is a major determinant of cortical bone thickness and non-vertebral fracture risk and mouse models with life-long Wnt16 inactivation revealed that WNT16 is a key regulator of cortical thickness. These studies, however, could not exclude that the effect of Wnt16 inactivation on cortical thickness might be caused by early developmental and/or growth effects. To determine the effect of WNT16 specifically on adult cortical bone homeostasis, Wnt16 was conditionally ablated in young adult and old mice through tamoxifen-inducible Cre-mediated recombination using CAG-Cre-ER; Wnt16 flox/flox (Cre-Wnt16 flox/flox) mice. First, 10-week-old Cre-Wnt16 flox/flox and Wnt16 flox/flox littermate control mice were treated with tamoxifen. Four weeks later, Wnt16 mRNA levels in cortical bone were reduced and cortical thickness in femur was decreased in Cre-Wnt16 flox/flox mice compared to Wnt16 flox/flox mice. Then, inactivation of Wnt16 in 47-week-old mice (evaluated four weeks later) resulted in a reduction of Wnt16 mRNA levels, cortical thickness and cortical bone strength with no effect on trabecular bone volume fraction. Mechanistic studies demonstrated that the reduced cortical bone thickness was caused by a combination of increased bone resorption and reduced periosteal bone formation. In conclusion, WNT16 is a crucial regulator of cortical bone thickness in young adult and old mice. We propose that new treatment strategies targeting the adult regulation of WNT16 might be useful to reduce fracture risk at cortical bone sites.
Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
Search for other papers by Carmen Corciulo in
Google Scholar
PubMed
Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
Search for other papers by Julia M Scheffler in
Google Scholar
PubMed
Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
Search for other papers by Piotr Humeniuk in
Google Scholar
PubMed
Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
Search for other papers by Alicia Del Carpio Pons in
Google Scholar
PubMed
Search for other papers by Alexandra Stubelius in
Google Scholar
PubMed
Search for other papers by Ula Von Mentzer in
Google Scholar
PubMed
Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
Search for other papers by Christina Drevinge in
Google Scholar
PubMed
Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
Search for other papers by Aidan Barrett in
Google Scholar
PubMed
Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
Search for other papers by Sofia Wüstenhagen in
Google Scholar
PubMed
Institute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, Turku Center for Disease Modeling, University of Turku, Turku, Finland
Search for other papers by Matti Poutanen in
Google Scholar
PubMed
Department of Drug Treatment, Sahlgrenska University Hospital, Gothenburg, Sweden
Search for other papers by Claes Ohlsson in
Google Scholar
PubMed
Search for other papers by Marie K Lagerquist in
Google Scholar
PubMed
Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
Search for other papers by Ulrika Islander in
Google Scholar
PubMed
Among patients with knee osteoarthritis (OA), postmenopausal women are over-represented. The purpose of this study was to determine whether deficiency of female sex steroids affects OA progression and to evaluate the protective effect of treatment with a physiological dose of 17β-estradiol (E2) on OA progression using a murine model. Ovariectomy (OVX) of female mice was used to mimic a postmenopausal state. OVX or sham-operated mice underwent surgery for destabilization of the medial meniscus (DMM) to induce OA. E2 was administered in a pulsed manner for 2 and 8 weeks. OVX of OA mice did not influence the cartilage phenotype or synovial thickness, while both cortical and trabecular subchondral bone mineral density (BMD) decreased after OVX compared with sham-operated mice at 8 weeks post-DMM surgery. Additionally, OVX mice displayed decreased motor activity, reduced threshold of pain sensitivity, and increased number of T cells in the inguinal lymph nodes compared to sham-operated mice 2 weeks after OA induction. Eight weeks of treatment with E2 prevented cartilage damage and thickening of the synovium in OVX OA mice. The motor activity was improved after E2 replacement at the 2 weeks time point, which was also associated with lower pain sensitivity in the OA paw. E2 treatment protected against OVX-induced loss of subchondral trabecular bone. The number of T cells in the inguinal lymph nodes was reduced by E2 treatment after 8 weeks. This study demonstrates that treatment with a physiological dose of E2 exerts a protective role by reducing OA symptoms.
Department of Biological and Medical Sciences, Oxford Brookes University, Oxford, UK
Search for other papers by Laura L Gathercole in
Google Scholar
PubMed
Search for other papers by Nikolaos Nikolaou in
Google Scholar
PubMed
Search for other papers by Shelley E Harris in
Google Scholar
PubMed
Department of Biological and Medical Sciences, Oxford Brookes University, Oxford, UK
Search for other papers by Anastasia Arvaniti in
Google Scholar
PubMed
Search for other papers by Toryn M Poolman in
Google Scholar
PubMed
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK
Search for other papers by Jonathan M Hazlehurst in
Google Scholar
PubMed
Search for other papers by Denise V Kratschmar in
Google Scholar
PubMed
Search for other papers by Marijana Todorčević in
Google Scholar
PubMed
Search for other papers by Ahmad Moolla in
Google Scholar
PubMed
Search for other papers by Niall Dempster in
Google Scholar
PubMed
Search for other papers by Ryan C Pink in
Google Scholar
PubMed
Search for other papers by Michael F Saikali in
Google Scholar
PubMed
Search for other papers by Liz Bentley in
Google Scholar
PubMed
Search for other papers by Trevor M Penning in
Google Scholar
PubMed
Search for other papers by Claes Ohlsson in
Google Scholar
PubMed
Search for other papers by Carolyn L Cummins in
Google Scholar
PubMed
Institute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, University of Turku, Turku, Finland
Search for other papers by Matti Poutanen in
Google Scholar
PubMed
Search for other papers by Alex Odermatt in
Google Scholar
PubMed
Search for other papers by Roger D Cox in
Google Scholar
PubMed
Search for other papers by Jeremy W Tomlinson in
Google Scholar
PubMed
Steroid 5β-reductase (AKR1D1) plays important role in hepatic bile acid synthesis and glucocorticoid clearance. Bile acids and glucocorticoids are potent metabolic regulators, but whether AKR1D1 controls metabolic phenotype in vivo is unknown. Akr1d1–/– mice were generated on a C57BL/6 background. Liquid chromatography/mass spectrometry, metabolomic and transcriptomic approaches were used to determine effects on glucocorticoid and bile acid homeostasis. Metabolic phenotypes including body weight and composition, lipid homeostasis, glucose tolerance and insulin tolerance were evaluated. Molecular changes were assessed by RNA-Seq and Western blotting. Male Akr1d1–/– mice were challenged with a high fat diet (60% kcal from fat) for 20 weeks. Akr1d1–/– mice had a sex-specific metabolic phenotype. At 30 weeks of age, male, but not female, Akr1d1–/– mice were more insulin tolerant and had reduced lipid accumulation in the liver and adipose tissue yet had hypertriglyceridemia and increased intramuscular triacylglycerol. This phenotype was associated with sexually dimorphic changes in bile acid metabolism and composition but without overt effects on circulating glucocorticoid levels or glucocorticoid-regulated gene expression in the liver. Male Akr1d1–/– mice were not protected against diet-induced obesity and insulin resistance. In conclusion, this study shows that AKR1D1 controls bile acid homeostasis in vivo and that altering its activity can affect insulin tolerance and lipid homeostasis in a sex-dependent manner.
